Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Receives Consensus Rating of “Moderate Buy” from Brokerages

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) has received a consensus rating of “Moderate Buy” from the seven analysts that are presently covering the company, MarketBeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, four have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $6.40.

MIST has been the subject of several recent research reports. Wall Street Zen cut Milestone Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Sunday, May 17th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Milestone Pharmaceuticals in a report on Tuesday, July 14th. Cantor Fitzgerald assumed coverage on shares of Milestone Pharmaceuticals in a research report on Thursday, August 20th. They set an “overweight” rating and a $3.00 target price for the company. Zacks Research raised shares of Milestone Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research report on Monday, July 13th. Finally, Wells Fargo & Company lowered their price target on shares of Milestone Pharmaceuticals from $8.00 to $7.00 and set an “overweight” rating for the company in a report on Thursday, May 14th.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Several large investors have recently modified their holdings of MIST. Guardian Wealth Advisors LLC NC boosted its position in Milestone Pharmaceuticals by 21.1% during the second quarter. Guardian Wealth Advisors LLC NC now owns 339,450 shares of the company’s stock valued at $455,000 after acquiring an additional 59,200 shares during the last quarter. ADAR1 Capital Management LLC acquired a new stake in Milestone Pharmaceuticals during the 2nd quarter worth about $134,000. TRU Independence Asset Management 2 LLC bought a new position in shares of Milestone Pharmaceuticals in the 2nd quarter worth about $201,000. Renaissance Technologies LLC bought a new position in shares of Milestone Pharmaceuticals in the 1st quarter worth about $154,000. Finally, Invesco Ltd. acquired a new position in shares of Milestone Pharmaceuticals in the 4th quarter valued at about $44,000. 86.18% of the stock is currently owned by institutional investors and hedge funds.

Milestone Pharmaceuticals Trading Up 1.7%

Shares of MIST stock opened at $1.18 on Thursday. Milestone Pharmaceuticals has a twelve month low of $1.00 and a twelve month high of $3.06. The stock’s fifty day simple moving average is $1.20 and its 200 day simple moving average is $1.47. The company has a quick ratio of 7.92, a current ratio of 8.13 and a debt-to-equity ratio of 3.25. The firm has a market capitalization of $146.91 million, a P/E ratio of -1.71 and a beta of 0.98.

Milestone Pharmaceuticals (NASDAQ:MIST) last posted its earnings results on Wednesday, August 12th. The company reported ($0.21) EPS for the quarter, missing the consensus estimate of ($0.20) by ($0.01). The company had revenue of $0.56 million for the quarter, compared to analyst estimates of $0.82 million. As a group, sell-side analysts predict that Milestone Pharmaceuticals will post -0.84 EPS for the current fiscal year.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on developing innovative therapies for respiratory diseases. The company’s research emphasizes both biologic and small-molecule approaches designed to improve mucociliary clearance, reduce airway inflammation and address chronic and refractory cough. Milestone’s pipeline targets key underserved conditions such as cystic fibrosis, primary ciliary dyskinesia and severe asthma.

Milestone’s lead product candidates are delivered through inhalation or systemic administration, reflecting the company’s commitment to optimizing therapeutic delivery directly to the lungs.